Dossier
contrast agents
Coverage of contrast agents in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
The U.S. experienced 227 active medication shortages in Q2 2026, with 48% being sole-source products and 10% involving life-saving contrast agents. GSK abandoned development of camlipixant, a chronic cough drug acquired for $2 billion, after Phase 3 trials showed limited efficacy.